This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Fully Human Anti-CD19 CAR (KITE)
Kite Pharma, Inc.
Drug Names(s): fully human anti-CD19 chimeric antigen receptor-based product candidate, engineered peripheral blood autologous T cell therapeutics (eACT)
Description: Kite Pharma is developing a fully-human anti-CD19 CAR product candidate for the treatment of B-cell lymphomas and leukemias.
Fully Human Anti-CD19 CAR (KITE) News
Pink Sheet Kite’s Axi-Cel CAR-T: No Adcomm, No Problem
Additional information available to subscribers only: